Developed US and EU access strategies for a novel compound
Introduction
Our client is developing a new compound for two respiratory indications; initially a rare condition, followed by a more common respiratory illness. The development team needs to understand how the initial price for the rare condition will impact US and EU payers’ evaluation when the product is submitted for the broader indication.
The Challenge
Our client sought comprehensive guidance on how to effectively position the product in order to optimize payer access and ensure sustainable long-term revenue growth.
Our Solution
- Collaborated with the brand team to share knowledge and plan the access stakeholders to target in primary research, focusing on experts in both indications of the client’s clinical program
- Developed research tools for interviews with KOLs, health economists advising NICE in the UK, HAS in France, ISCIII in Spain, and pharmacy directors at major US health plans.
- Recommended approaches for product positioning in each country, optimizing access based on TPP scenarios, and addressing endpoints and pricing implications for each indication
Value Delivered
We delivered strategic insights that significantly enhanced the client’s clinical program and refined revenue forecasts for the new compound. These insights helped the client make informed decisions, ultimately improving the product’s market positioning and financial projections.
